Achieving Long-Term Optimal Outcomes in Geriatric Depression and Anxiety

CNS Spectrums

Volumn 8, Issue 12 SUPPL. 3, 2003, Pages 27-34

  Mulsant, Benoit H ^a   Whyte, Ellen ^b   Lenze, Eric J ^b   Lotrich, Francis ^b   Karp, Jordan F ^b   Pollock, Bruce G ^b   Reynolds III, Charles F ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; PSYCHOTROPIC AGENT; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TRICYCLIC ANTIDEPRESSANT AGENT;

AGED; ANXIETY; AROUSAL; CLINICAL RESEARCH; COMORBIDITY; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; EJACULATION DISORDER; ELDERLY CARE; ERECTILE DYSFUNCTION; GERIATRIC CARE; HUMAN; HYPONATREMIA; INSOMNIA; OUTCOMES RESEARCH; PATIENT EDUCATION; PRIORITY JOURNAL; PSYCHOTHERAPY; REMISSION; REVIEW; RISK FACTOR; SEXUAL DYSFUNCTION; SIDE EFFECT; SYMPTOMATOLOGY; TAXONOMY;

EID: 1642501881     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900008257     Document Type: Review

References (134)

1. Lenze EJ, Mulsant BH, Shear MK, et al. Comorbid anxiety disorders in depressed elderly patients. Am J Psychiatry. 2000;5:722-728.
2. Lenze EJ, Mulsant BH, Shear MK, Houck P, Reynolds CF 3rd. Anxiety symptoms in elderly patients with depression: what is the best approach to treatment? Drugs Aging. 2002;10:753-760.
3. Mulsant BH, Ganguli M. Epidemiology and diagnosis of depression in late life. J Clin Psychiatry. 1999;60(suppl 20):9-15.
4. Mulsant BH, Pollock BG. Psychopharmacology. In: Blazer DG, Steffens DC, Busse EW, eds. The American Psychiatric Publishing Textbook of Geriatric Psychiatry. 3rd ed. Washington, DC: American Psychiatric Publishing; 2004:455-485.
5. Bump GM, Mulsant BH, Pollock BG, et al. Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly. Depress Anxiety. 2001;1:38-44.
6. Dew MA, Reynolds CF 3rd, Mulsant B, et al. Initial recovery patterns may predict which maintenance therapies for depression will keep older adults well. J Affect Disord. 2001;2:155-166.
7. Reynolds CF 3rd, Frank E, Peril JM, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA. 1999;1:39-45.
8. Reynolds CF 3rd, Peril JM, Frank E, et al. Three-year outcomes of maintenance nortriptyline treatment in late-life depression: a study of two fixed plasma levels. Am J Psychiatry. 1999;8:1177-1181.
9. Walters G, Reynolds CF 3rd, Mulsant BH, Pollock BG. Continuation and maintenance pharmacotherapy in geriatric depression: an open-trial comparison of paroxetine and nortriptyline in patients older than 70 years. J Clin Psychiatry. 1999;60(suppl 2):21-25.
10. Harman JS, Rollman BL, Hanusa BH, Lenze EJ, Shear MK. Physician office visits of adults for anxiety disorders in the United States, 1985-1998. J Gen Int Med. 2002;3:165-172.
11. Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA. National trends in the outpatient treatment of depression. JAMA. 2002;2:203-209.
12. Pincus HA, Tanielian TL, Marcus SC, et al. Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. JAMA. 1998;7:526-531.
13. Harman JS, Mulsant BH, Kelleher KJ, Schulberg HC, Kupfer DJ, Reynolds CF 3rd. Narrowing the gap in treatment of depression. Int J Psychiatry Med. 2001;3:239-253.
14. Brown C, Schulberg HC, Madonia MJ, Shear MK, Houck PR. Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. Am J Psychiatry. 1996;10:1293-1300.
15. Kessler RC, Berglund P, Demler O, et al. National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;23:3095-3105.
16. Rost K, Nutting P, Smith J, Elliott CE, Dickinson M. Managing depression as a chronic disease: a randomised trial of ongoing treatment in primary care. BMJ. 2002;7370:934.
17. Schulberg HC, Block MR, Madonia MJ, et al. The 'usual care' of major depression in primary care practice. Arch Fam Med. 1997;4:334-339.
18. Unützer J, Katon W, Callahan CM, et al. Depression treatment in a sample of 1,801 depressed older adults in primary care. J Am Geriatr Soc. 2003;4:505-514.
19. Wang PS, Berglund P, Kessler RC. Recent care of common mental disorders in the United States. J Gen Intern Med. 2000;15:284-292.
20. Wells KB, Katon W, Rogers B, Camp P. Use of minor tranquilizers and antidepressant medications by depressed outpatients: results from the medical outcomes study. Am J Psychiatry. 1994;5:694-700.
21. Wells KB, Sherbourne C, Schoenbaum M, et al. Impact of disseminating quality improvement programs for depression in managed primary care: a randomized controlled trial. JAMA. 2000;24:3204.
22. Young AS, Klap R, Sherbourne CD, Wells KB. The quality of care for depressive and anxiety disorders in the United States. Arch Gen Psychiatry. 2001;1:55-61.
23. Meyers BS, Sirey JA, Bruce M, et al. Predictors of early recovery from major depression among persons admitted to community-based clinics: an observational study. Arch Gen Psychiatry. 2002;8:729-735.
24. Sirey JA, Meyers BS, Bruce ML, Alexopoulos GS, Perlick DA, Raue P. Predictors of antidepressant prescription and early use among depressed outpatients. Am J Psychiatry. 1999;5:690-696.
25. Wells KB, Norquist G, Benjamin B, Rogers W, Kahn K, Brook R. Quality of antidepressant medications prescribed at discharge to depressed elderly patients in general medical hospitals before and after prospective payment system. Gen Hosp Psychiatry. 1994;1:4-15.
26. Evers MM, Samuels SC, Lantz M, Khan K, Brickman AM, Marin DB. The prevalence, diagnosis and treatment of depression in dementia patients in chronic care facilities in the last six months of life. Int J Geriatr Psychiatry. 2002;5:464-472.
27. Kamath M, Finkel SI, Moran MB. A retrospective chart review of antidepressant use, effectiveness, and adverse effects in adult age 70 and older. Am J Geriatr Psychiatry. 1996;2:167-172.
28. Luber MP, Meyers BS, Williams-Russo PG, et al. Depression and service utilization in elderly primary care patients. Am J Geriatr Psychiatry. 2001;2:169-176.
29. Orrell M, Collins E, Shergill S, Katona C. Management of depression in the elderly by general practitioners: I. Use of antidepressants. Fam Pract. 1995;1:5-11.
30. Rojas-Fernandez C, Thomas VS, Carver D, Tonks R. Suboptimal use of antidepressants in the elderly: a population-based study in Nova Scotia. Clin Ther. 1999;11:1937-1950.
31. Steffens DC, Skoog I, Norton MC, et al. Prevalence of depression and its treatment in an elderly population: the Cache County study. Arch Gen Psychiatry. 2000;6:601-607.
32. Unützer J, Patrick DL, Simon G, et al. Depressive symptoms and the cost of health services in HMO patients aged 65 years and older. A 4-year prospective study. JAMA. 1997;20:1618-1623.
33. Unützer J, Katon W, Callahan CM, et al. IMPACT Investigators. Improving Mood-Promoting Access to Collaborative Treatment. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA. 2002;22:2836-2845.
34. Roy-Byrne PP, Stein MB, Russo J, et al. Panic disorder in the primary care setting: comorbidity, disability, service utilization, and treatment. J Clin Psychiatry. 1999;7:492-499.
35. Andrews G, Sanderson K, Slade T, Issakidis C. Why does the burden of disease persist? Relating the burden of anxiety and depression to effectiveness of treatment. Bull World Health Org. 2000;4:446-454.
36. Lin EH, Katon WJ, Simon GE, et al. Low-intensity treatment of depression in primary care: is it problematic? Gen Hosp Psychiatry. 2000;2:78-83.
37. Meyers, BS. Effectiveness vs. efficacy of antidepressants for the treatment of late-life depression: Introduction to a retrospective chart review of antidepressants use, effectiveness, and adverse effects in adults age 70 and older. Am J Geriatr Psychiatry. 1996;2:164-166.
38. Nutting PA, Rost K, Smith J, Werner JJ, Elliot C. Competing demands from physical problems: effect on initiating and completing depression care over 6 months. Arch Fam Med. 2000;10:1059-1064.
39. Unützer J, Katon W, Sullivan M, Miranda J. Treating depressed older adults in primary care: narrowing the gap between efficacy and effectiveness. 1999;2:225-256.
40. Rost K, Nutting P, Smith J, Coyne JC, Cooper-Patrick L, Rubenstein L. The role of competing demands in the treatment provided primary care patients with major depression. Arch Fam Med. 2000;2:150-154.
41. Callahan CM, Hendrie HC, Tierney WM. The recognition and treatment of late-life depression: a view from primary care. Int J Psychiatry Med. 1996;2:155-171.
42. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry. 2002;3:469-473.
43. Boudreau DM, Capoccia KL, Sullivan SD, et al. Collaborative care model to improve outcomes in major depression. Ann Pharmacother. 2002;4:585-591.
44. Hedrick SC, Chaney EF, Felker B, et al. Effectiveness of collaborative care depression treatment in Veterans' Affairs primary care. J Gen Int Med. 2003;1:9-16.
45. Katon W, Von Korff M, Lin E, et al. Collaborative management to achieve depression treatment guidelines. J Clin Psychiatry. 1997;58(suppl 1):20-23.
46. Katon W, Von Korff M, Lin E, et al. Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized trial. Arch Gen Psychiatry. 1999;12:1109-1115.
47. Katon W, Russo J, Von Korff M, et al. Long-term effects of a collaborative care intervention in persistently depressed primary care patients. J Gen Int Med. 2002;10:741-748.
48. Katzelnick DJ, Simon GE, Pearson SD, et al. Randomized trial of a depression management program in high utilizers of medical care. Arch Fam Med. 2000;4:345-351.
49. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. JAMA 2002;14:1775-1779.
50. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, Part 2. JAMA. 2002;15:1909-1914.
51. Ford DE, Pincus HA, Unützer J, Bauer MS, Gonzalez JJ, Wells KB. NIMH Affective Disorders Workgroup. Practice-based interventions. Ment Health Servs Res. 2002;4:199-204.
52. Mulsant BH, Alexopoulos GS, Reynolds CF 3rd, et al. The PROSPECT Study Group. Pharmacological treatment of depression in older primary care patients: the PROSPECT algorithm. Int J Geriatr Psychiatry. 2001;6:585-592.
53. Schulberg HC, Bryce C, Chism K, et al. The PROSPECT Group. Managing late-life depression in primary care practice: a case study of the Health Specialist's role. Int J Geriatr Psychiatry. 2001;6:577-584.
54. Craske MG, Roy-Byrne P, Stein MB, et al. Treating panic disorder in primary care: a collaborative care intervention. Gen Hosp Psychiatry. 2002;3:148-155.
55. Katon WJ, Roy-Byrne P, Russo J, Cowley D. Cost-effectiveness and cost offset of a collaborative care intervention for primary care patients with panic disorder. Arch Gen Psychiatry. 2002;12:1098-1104.
56. Mauksch LB, Tucker SM, Katon WJ, et al. Mental illness, functional impairment, and patient preferences for collaborative care in an uninsured, primary care population. J Fam Pract. 2001;1:41-47.
57. Roy-Byrne PP, Katon W, Cowley DS, Russo J. A randomized effectiveness trial of collaborative care for patients with panic disorder in primary care. Arch Gen Psychiatry. 2001;9:869-876.
58. Thomas L, Mulsant BH, Solano FX, et al. Response speed and rate of remission in primary and specialty care of elderly patients with depression. Am J Geriatr Psychiatry. 2002;5:583-591.
59. Simon GE, Manning WG, Katzelnick DJ, Pearson SD, Henk HJ, Helstad CS. Cost-effectiveness of systematic depression treatment for high utilizers of general medical care. Arch Gen Psychiatry. 2001;2:181-187.
60. Simon GE, Von Korff M, Ludman EJ, et al. Cost-effectiveness of a program to prevent depression relapse in primary care. Medical Care. 2002;10:941-950.
61. Von Korff M, Katon W, Bush T, et al. Treatment costs, cost offset, and cost-effectiveness of collaborative management of depression. Psychosom Med. 1998;2:143-149.
62. Hunkeler EM, Meresman JF, Hargreaves WA, et al. Efficacy of nurse telehealth care and peer support in augmenting treatment of depression in primary care. Arch Fam Med. 2000;8:700-708.
63. Peveler R, George C, Kinmonth AL, Campbell M, Thompson C. Effect of antidepressant drug counseling and information leaflets on adherence to drug treatment in primary care: randomised controlled trial. BMJ. 1999;7210:612-615.
64. Bartels SJ, Coakley E, Oxman TE, et al. Suicidal and death ideation in older primary care patients with depression, anxiety, and at-risk alcohol use. Am J Geriatr Psychiatry. 2002;4:417-427.
65. Devanand DP. Comorbid psychiatric disorders in late life depression. Biol Psychiatry. 2002;3:236-242.
66. Koike AK, Unützer J, Wells KB. Improving the care for depression in patients with comorbid medical illness. Am J Psychiatry. 2002;10:1738-1745.
67. Mulsant BH, Pollock BG. Treatment-resistant depression in late life. J Geriatr Psychiatry Neurol. 1998;4:186-193.
68. Oslin DW, Datto CJ, Kallan MJ, et al. Association between medical comorbidity and treatment outcomes in late-life depression. J Am Geriatr Soc. 2002;5:823-828.
69. Colenda CC, Mickus MA, Marcus SC, Tanielian TL, Pincus HA. Comparison of adult and geriatric psychiatric practice patterns: findings from the American Psychiatric Association's Practice Research Network. Am J Geriatr Psychiatry. 2002;5:609-617.
70. Alexopoulos GS, Meyers BS, Young RC, Mattis S, Kakuma T. The course of geriatric depression with "reversible dementia": a controlled study. Am J Psychiatry. 1993;11:1693-1699.
71. Alexopoulos GS, Meyers BS, Young RC, et al. Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry. 2000;3:285-290.
72. Chen P, Ganguli M, Mulsant BH, DeKosky ST. The temporal relationship between depressive symptoms and dementia: a community-based prospective study. Arch Gen Psychiatry. 1999;3:261-266.
73. Oslin DW, Katz IR, Edell WS, Ten Have TR. Effects of alcohol consumption on the treatment of depression among elderly patients. Am J Geriatr Psychiatry. 2000;3:215-220.
74. Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002;3:310-314.
75. Fava M, Alpert J, Nierenberg A, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol. 2002;4:379-387.
76. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry. 2000;9:1501-1504.
77. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234-241.
78. Cuffel BJ, Azocar F, Tomlin M, Greenfield SF, Busch AB, Croghan TW. Remission, residual symptoms, and nonresponse in the usual treatment of major depression in managed clinical practice. J Clin Psychiatry. 2003;4:397-402.
79. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50:97-108.
80. Lin EH, Katon WJ, VonKorff M, et al. Relapse of depression in primary care. Rate and clinical predictors. Arch Fam Med. 1998;5:443-449.
81. Prien RF, Kupfer DJ. Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry. 1986;1:18-23.
82. Fava GA, Grandi S, Zielezny M, Rafanelli C, Canestrari R. Four-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Randomized controlled trial. Am J Psychiatry. 1996;7:945-947.
83. Taylor MP, Reynolds CF 3rd, Frank E, et al. Which elderly depressed patients remain well on maintenance interpersonal psychotherapy alone?: report from the Pittsburgh study of maintenance therapies in late-life depression. Depress Anxiety. 1999;2:55-60.
84. Thase ME, Simons AD, McGeary J, et al. Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment. Am J Psychiatry. 1992;8:1046-1052.
85. Sackeim HA, Prudic J, Devanand DP, Decina P, Kerr B, Malitz S. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol. 1990;2:96-104.
86. Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001;10:1299-1307.
87. Mulsant BH, Houck PH, Gildengers AG, et al. What is the optimal duration of an acute antidepressant trial when treating geriatric depression? Am J Geriatric Psychiatry. 2002;2(suppl 1):75.
88. Houck PR, Mazumdar S, Mulsant BH, Pollock BG, Dew MA, Reynolds CF 3rd. An intent-to-treat method for enhancing analysis of clinical trials with rescue medication: A mixed model approach. Psychopharmacol Bull. 2003;1:79-89.
89. Opdyke KS, Reynolds CF 3rd, Frank E, et al. Effect of continuation treatment on residual symptoms in late-life depression: how well is "well"? Depress Anxiety. 1997;6:312-319.
90. Buysse DJ, Reynolds CF 3rd, Houck PR, et al. Does lorazepam impair the antidepressant response to nortriptyline and psychotherapy? J Clin Psychiatry. 1997;10:426-432.
91. Menza M, Marin H, Opper RS. Residual symptoms in depression: can treatment be symptom-specific? J Clin Psychiatry. 2003;5:516-523.
92. Alexopoulos GS, Katz IR, Reynolds CF, Carpenter D, Docherty JP. Pharmacotherapy of depressive disorders in older patients. Expert Consensus Guidelines Series. Postgrad Med. Special Report. 2001.
93. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1990;12:1093-1099.
94. Perlis RH, Nierenberg AA, Alpert JE, et al. Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. J Clin Psychopharmacol. 2002;5:474-480.
95. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998;2:196-201.
96. Kobak KA, Taylor L, Katzelnick DJ, Olson N, Clagnaz P, Henk HJ. Antidepressant medication management and Health Plan Employer Data Information Set (HEDIS) criteria: reasons for nonadherence. J Clin Psychiatry. 2002;8:727-372.
97. Gilbody S, Whitty P, Grimshaw J, Thomas R. Educational and organizational interventions to improve the management of depression in primary care: a systematic review. JAMA. 2003;23:3145-3151.
98. Oxman TE, Dietrich AJ, Williams JW Jr, Kroenke K. A three-component model for reengineering systems for the treatment of depression in primary care. Psychosomatics. 2002;6:441-450.
99. Cruz M, Pincus HA. Research on the influence that communication in psychiatric encounters has on treatment. Psychiatr Serv. 2002;10:1253-1265.
100. Miller MD, Frank E, Reynolds CF 3rd. The art of clinical management in pharmacologic trials with depressed elderly patients: lessons from the Pittsburgh Study of Maintenance Therapies in Late-Life Depression. Am J Geriatr Psychiatry. 1999;3:228-234.
101. Sherrill JT, Frank E, Geary M, Stack JA, Reynolds CF 3rd. Psychoeducational workshops for elderly patients with recurrent major depression and their families. Psychiatr Serv. 1997;1:76-81.
102. Roeloffs C, Sherbourne C, Unützer J, Fink A, Tang L, Wells KB. Stigma and depression among primary care patients. Gen Hosp Psychiatry. 2003;5:311-315.
103. Sirey JA, Bruce ML, Alexopoulos GS, et al. Perceived stigma as a predictor of treatment discontinuation in young and older outpatients with depression. Am J Psychiatry. 2001;3:479-481.
104. Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995;1:67-74.
105. Bull SA, Hunkeler EM, Lee JY, et al. Discontinuing or switching selective serotonin reuptake inhibitors. Ann Pharmacother. 2002;4:578-584.
106. Demyttenaere K, Enzlin P, Dewe W, et al. Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events. J Clin Psychiatry. 2001;62(suppl 22):30-33.
107. Maidment R, Livingston G, Katona C. Just keep taking the tablets: adherence to antidepressant treatment in older people in primary care. Int J Geriatr Psychiatry. 2002;8:752-757.
108. Depression Guideline Panel. Depression in Primary Care: Vol. 2. Treatment of Major Depression. Rockville, MD: Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; 1993. Clinical Practice Guideline No. 5, publication No. 93-0551.
109. Frank E, Perel JM, Mallinger AG, Thase ME, Kupfer DJ. Relationship of pharmacologic compliance to long-term prophylaxis in recurrent depression. Psychopharmacol Bull. 1992;3:231-235.
110. Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1992;10:769-773.
111. Reynolds CF 3rd, Alexopoulos GS, Katz IR, Liebowitz BD. Chronic depression in the elderly: approaches for prevention. Drugs Aging. 2001;7:507-514.
112. Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA. 2002;11:1403-1409.
113. Golden RN, Nemeroff CB, McSorley P, Pitts CD, Dube EM. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry. 2002;7:577-584.
114. Rapaport MH, Schneider LS, Dunner DL, Davies JT, Pitts CD. Efficacy of controlled-release paroxetine in the treatment of late-life depression. J Clin Psychiatry. 2003;64:1065-1074.
115. Keller MB, Hirschfeld RM, Demyttenaere K, Baldwin DS. Optimizing outcomes in depression: focus on antidepressant compliance. Int Clin Psychopharmacol. 2002;6:265-271.
116. Mulsant BH, Pollock BG, Nebes R, et al. A twelve-week, double-blind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients. Am J Geriatr Psychiatry. 2001;4:406-414.
117. Solai LK, Mulsant BH, Pollock BG. Selective serotonin reuptake inhibitors for late-life depression: a comparative review. Drugs Aging. 2001;5:355-368.
118. Steffens DC, Krishnan KR, Helms MJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety. 1997;1:10-18.
119. Thompson C, Peveler RC, Stephenson D, McKendrick J. Compliance with antidepressant medication in the treatment of major depressive disorder in primary care: a randomized comparison of fluoxetine and a tricyclic antidepressant. Am J Psychiatry. 2000;3:338-343.
120. Fabian TJ, Amico JA, Kroboth PD, et al. Paroxetine-induced hyponatremia in older adults: a twelve-week prospective study. Arch Int Med. In press.
121. Mulsant BH, Pollock BG, Kirshner M, Shen C, Dodge H, Ganguli M. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry. 2003;2:198-203.
122. Nebes RD, Pollock BG, Mulsant BH, et al. Low-level serum anticholinergicity as a source of baseline cognitive heterogeneity in geriatric depressed patients. Psychopharmacol Bull. 1997;4:715-720.
123. Dording CM, Mischoulon D, Petersen TJ, et al. The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. Ann Clin Psychiatry. 2002;3:143-147.
124. Fava M. Management of nonresponse and intolerance: switching strategies. J Clin Psychiatry. 2000;61(suppl 2):10-12.
125. Posternak MA, Zimmerman M. The effectiveness of switching antidepressants during remission: a case series of depressed patients who experienced intolerable side effects. J Affect Disord. 2002;69:237-240.
126. Nierenberg AA, Adler LA, Peselow E, Zornberg G, Rosenthal M. Trazodone for antidepressant-associated insomnia. Am J Psychiatry. 1994;7:1069-1072.
127. Nurnberg HG, Hensley PL, Gelenberg AJ, Fava M, Lauriello J, Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA. 2003;1:56-64.
128. Gitlin MJ, Suri R, Altshuler L, Zuckerbrow-Miller J, Fairbanks L. Bupropion-sustained release as a treatment for SSRI-induced sexual side effects. J Sex Marital Ther. 2002;2:131-138.
129. Kennedy SH, McCann SM, Masellis M, et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry. 2002;3:181-186.
130. Masand PS, Ashton AK, Gupta S, Frank B. Sustained-release bupropion for selective serotonin reuptake inhibitor-induced sexual dysfunction: a randomized, double-blind, placebo-controlled, parallel-group study. Am J Psychiatry. 2001;5:805-807.
131. Joo JH, Lenze EJ, Mulsant BH, et al. Risk factors for falls during treatment of late-life depression. J Clin Psychiatry. 2002;10:936-941.
132. Pollock B, Mulsant BH. Psychopharmacology. In: Crome P, Ford G, eds. Drugs and the Older Person. London, England: Imperial College Press; 2000:275-303.
133. Clayton AH, McGarvey EL, Abouesh AI, Pinkerton RC. Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. J Clin Psychiatry. 2001;3:185-190.
134. Walker PW, Cole JO, Gardner EA, et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry. 1993;12:459-465.